WO2017192535A8 - Method of treating cardiovascular disease and cystic fibrosis with combination product containing hydroxytyrosol - Google Patents

Method of treating cardiovascular disease and cystic fibrosis with combination product containing hydroxytyrosol Download PDF

Info

Publication number
WO2017192535A8
WO2017192535A8 PCT/US2017/030566 US2017030566W WO2017192535A8 WO 2017192535 A8 WO2017192535 A8 WO 2017192535A8 US 2017030566 W US2017030566 W US 2017030566W WO 2017192535 A8 WO2017192535 A8 WO 2017192535A8
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disease
product containing
cystic fibrosis
combination product
treating cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/030566
Other languages
French (fr)
Other versions
WO2017192535A1 (en
Inventor
Thomas Gutierrez
Michael Pucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oliventures Inc
Original Assignee
Oliventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oliventures Inc filed Critical Oliventures Inc
Publication of WO2017192535A1 publication Critical patent/WO2017192535A1/en
Publication of WO2017192535A8 publication Critical patent/WO2017192535A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an improved method for treating or preventing a cardiovascular disease or a related condition utilizing hydroxytyrosol and one of a vitamin or an anti-inflammatory.
PCT/US2017/030566 2016-05-03 2017-05-02 Method of treating cardiovascular disease and cystic fibrosis with combination product containing hydroxytyrosol Ceased WO2017192535A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331031P 2016-05-03 2016-05-03
US62/331,031 2016-05-03

Publications (2)

Publication Number Publication Date
WO2017192535A1 WO2017192535A1 (en) 2017-11-09
WO2017192535A8 true WO2017192535A8 (en) 2017-12-28

Family

ID=60203370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/030566 Ceased WO2017192535A1 (en) 2016-05-03 2017-05-02 Method of treating cardiovascular disease and cystic fibrosis with combination product containing hydroxytyrosol

Country Status (1)

Country Link
WO (1) WO2017192535A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1010766B (en) * 2023-06-16 2024-09-17 Ιουλια Τσετη Orally administrated composition of hydroxytyrosol with acetylsalicylic acid and/or one or more satins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0814726B1 (en) * 2007-07-23 2020-04-14 Euromed, S.A process for preparing a nutritional product and nutritional product
WO2015193630A1 (en) * 2014-06-18 2015-12-23 Evolva Sa Treatment of cardiovascular risk in patients with cardiovascular disease and/or diabetes

Also Published As

Publication number Publication date
WO2017192535A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
WO2017027810A3 (en) Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders
WO2015157070A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2016122146A8 (en) Novel promoter and uses thereof
HK1251482A1 (en) Composition and method for treating complement-mediated disease
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP4316592A3 (en) Carbamoyl phenylalaninol compounds and uses thereof
GB201903787D0 (en) Microcapsules containing curcumin, and methods for the production thereof
WO2016167944A8 (en) Compositions and methods for treating autism
WO2017222819A3 (en) Solid state forms of ixazomib citrate
WO2017192535A8 (en) Method of treating cardiovascular disease and cystic fibrosis with combination product containing hydroxytyrosol
WO2017036488A8 (en) Combination product for assisting with relaxation and sleep
WO2015175884A3 (en) Compositions and methods for treating and preventing pancreatitis, renal injury and cancer
WO2018094122A8 (en) Methods and compositions for treating atopic dermatitis
WO2018148629A3 (en) Methods and compositions for treating neurodegeneration and fibrosis
Garg et al. On asymptotic behavior of U-statistics for associated random variables
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
榊原美穂 The British Boy Bands and Their Influence on Japanese People and the Japanese Music Scene
TH66701S1 (en) The lamp
TH164513S (en) The lamp
TH67853S1 (en) The lamp
TH66697S1 (en) The lamp
TH66699S1 (en) The lamp
TH164511S (en) The lamp
TH67852S1 (en) The lamp
TH164512S (en) The lamp

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17793122

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17793122

Country of ref document: EP

Kind code of ref document: A1